Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: Thermo Cardiosystems HeartMate

This article was originally published in The Gray Sheet

Executive Summary

Thermo Cardiosystems HeartMate: Left ventricular-assist system is implanted for the first time in the U.K. as a permanent alternative to heart transplant. The procedure is the first of a "series of implants in which the electric LVAS will be used to permanently take over the pumping function of natural hearts too weak to beat adequately on their own," the company says. Woburn, Massachusetts-based Thermo Cardiosystems says it is "actively working" with FDA to begin a study of the HeartMate as a "permanent alternative to other medical treatments for patients who do not qualify for transplants." HeartMate was approved by FDA in October 1994 for use as a bridge-to-heart transplant ("The Gray Sheet" Oct. 10, 1994, p. 1)...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT004991

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel